In vitro studies demonstrated that PSMA-specific, TGF-β–resistant CD8+ T cells from mCRPC patients can be robustly expanded and effectively counteract the immunosuppressive TME, exhibiting significant cytotoxicity against PSMA-expressing tumor cell lines. This evidence concerns the gene CD8A and neoplasm.